 |
|
|
   
|
New Acne System Clinically Proven to Provide Best-in-Class Penetration and Efficacy
Long Beach, California — February 2, 2007 — Obagi Medical Products, Inc.
(NASD:OMPI), the leader in skin transformation, today announced the launch of a
breakthrough acne therapy skincare line of topical products – CLENZIderm M.D.™
Acne Therapeutic System. The new acne kit boasts an advanced, patented Soluzyl
Technology™ that liquefies Benzoyl Peroxide (BPO) on contact, which helps to
deliver greater follicular penetration and rapid lesion reduction. The science
validating the system will be the subject of two posters at the American Academy
of Dermatology (AAD) convention in Washington D.C., beginning February 2, 2007.
“We are very excited to bring novel and efficacious technology to the field of
acne treatment, a market valued at $XX million,” said Steven Carlson, President
of Obagi. “Studies indicate that no other single acne treatment or combination
therapy is proven to work on all three causes of acne, including excess oil,
acne-causing bacteria and clogged pores. We believe this scientific breakthrough
represents a transformation in the acne category and firmly establishes a new
market opportunity for Obagi science.”
The CLENZIderm M.D.™ Acne Therapeutic System uses a combination of salicylic
acid and a new, revolutionary gel form of BPO that allows for deeper penetration
to control acne quickly. Most BPO’s are formulated with insoluble macro-crystals
that, when applied, remain largely on the surface of the skin because they are
too big to penetrate its surface. Obagi’s patented Soluzyl Technology™ liquefies
the BPO on the surface of the skin for greater follicular penetration.
CLENZIderm M.D.™ Acne Therapeutic System will be previewed at the AAD
accompanied by posters detailing the comparison of BPO/Clindamycin combination
vs. CLENZIderm M.D.™ Acne Therapeutic System. The posters highlight the fact
that consistent use of CLENZIderm M.D.™ Acne Therapeutic System results in a
greater reduction of follicular acne in as early as eight hours and demonstrates
both a 52% reduction in inflammatory lesions and a 34% reduction in non-
inflammatory lesions in two weeks. CLENZIderm M.D.™ Acne Therapeutic System has
also shown 80% patient satisfaction by improving the appearance of acne through
the rapid clearing of lesions.
CLENZIderm M.D.™ Acne Therapeutic System is easy to use, highly effective and
addresses the challenge of achieving superior patient-compliance results. Each
step in the CLENZIderm M.D.™ Acne Therapeutic System is designed to complement
one another. The Daily Care Foaming Cleanser is used to first remove excess
sebum from the skin. The Pore Therapy acts as an exfoliator and removes dead
skin cells, priming the skin for the application of the BPO. Lastly, the Serum
Gel, containing the Soluzyl Technology™ and BPO, accelerates follicular
penetration by delivering medication deep into the pores.
CLENZIderm M.D.™ Acne Therapeutic System products will retail as a kit and will
be available in dermatologists’ and plastic surgeons’ offices nationwide
beginning February 2007.
About Obagi Medical Products, Inc.
Obagi, a leader in the physician-dispensed skin care channel develops and
commercializes skin health products for the dermatology, plastic surgery, and
related Aesthetic markets. Using its Penetrating Therapeutics™ technologies,
Obagi’s products are designed to improve penetration of agents across the skin
barrier for common and visible skin conditions in adult skin such as chloasma,
melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its
first skincare system, Obagi Nu-Derm, in 1988; and in 2004 launched the first
and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx.
Obagi System products are only available through physicians. Visit
www.obagi.com for information.
|
|
|
|